Recent News & Research

*October 2022* Introduction There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combination in relation to chemotherapy alone in this patient population.…

*December 2022* This video presentation features perspectives from lung cancer experts Drs Alexander Spira and Helena Yu and discusses the following: What is an antibody-drug conjugate? HER-2 positive NSCLC Targeting HER3 NSCLC TROP2-directed treatment Novel Agents Watch video here.

*December 2022* Newly diagnosed patients with non-small cell lung cancer (NSCLC) benefit tremendously from next-generation sequencing (NGS) to test for driver mutations and determine the best first-line treatment. But NGS platforms, such as parallel DNA sequencing, can have longer turnaround times than non-NGS testing, and "elays in time to treatment…

*December 2022* The treatment of LUAD-LM is particularly challenging and intrathecal pemetrexed is a potential therapeutic strategy for it, but still faces many obstacles caused by repeated lumbar puncture. We performed a prospective phase I study on 33 refractory LUAD-LM patients, aimed at assessing the safety, pharmacokinetic and clinical activity…

*December 2022* Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Dr. Triparna Sen as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC,…

*November 2022* Melina E. Marmarelis, MD, medical director of Penn Medicine Mesothelioma and Pleural Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, reports the rationale and key findings from the Chrysalis-2 trial (NCT04077463) of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC). A cohort…

*November 2022* The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of…